Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2

Rafael Holdings

Rafael Holdings

RFL

0.00


Overview

  • U.S. biotechnology firm's fiscal Q3 revenue fell yr/yr, net loss narrowed

  • Company completed last patient visit in pivotal Phase 3 TransportNPC trial


Outlook

  • Company expects to submit NDA for Trappsol Cyclo in H2 2026

  • Company sees high unmet need in NPC market as a potential opportunity


Result Drivers

  • CYCLICAL THERAPEUTIC EXPENSES - Higher research and development costs driven by consolidation of Cyclo Therapeutic's expenses after March 2025 acquisition

  • LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to reduced payroll, stock-based compensation, and professional fees, partially offset by Cyclo expenses


Company press release: ID:nGNX9xMmYD


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$179,000

Q3 EPS

-$0.08

Q3 Net Income Attributable To Co

-$4.23 mln

Q3 Operating Income

-$6.87 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.